I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

I-Mab Corporate Analyst Meeting Transcript

Apr 26, 2021 / 12:00PM GMT
Release Date Price: $64.23 (+0.82%)
Jielun Zhu
I-Mab - CFO & Director

Good morning or good evening, everyone. Welcome to the 2021 I-Mab Biopharma R&D Day. My name is Jielun Zhu, Chief Financial Officer of I-Mab. I will be your host today.

First, I would like to welcome everyone on behalf of I-Mab. Thank you very much for joining our discussion this morning or this evening. Since 2016, I-Mab has continued to develop into an innovation-driven global biotech company focused on the discovery and development of novel and highly differentiated biologics in immuno-oncology and autoimmune diseases. And now we are well on our way to becoming a biopharma with the near-term commercialization prospect of our first clinical assets.

Now let me introduce the senior management team with me today. We have Dr. Jingwu Zang, Founder and Chairman; Dr. Joan Shen, Chief Executive Officer; and Dr. Taylor Guo, Chief Scientific Officer. They will share with you our overall R&D strategy and the latest progress of I-Mab's key pipeline assets, including some new clinical data we have yet to present before today. For today's event, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot